РОЛЬ ИНТЕРЛЕЙКИНА-18 В РАЗВИТИИ МЕТАБОЛИЧЕСКОГО СИНДРОМА
- Авторы:Шукурлаева Мехринисо Хайрулло кизи, Сабирова Рихси Абдукадировна, Алимбекова Лобархон Уткуровна
- Дата публикации:March 26, 2026
- Тип:Статья
- DOI: 10.64156/mju.9128 Скопировано
- Том / № Выпуска:Том 1 №2 (2026)
Аннотация
Аннотация: Почки играют важную роль в организме человека. Профилактика и эффективное лечение повреждений почек являются одной из актуальных задач. В данной статье показана важность использования биомаркера интерлейкина-18 для ранней диагностики повреждений почек. Интерлейкин-18 является важным биомаркером повреждений почек при метаболическом синдроме.
Ключевые слова: метаболический синдром, повреждение почек, интерлейкин-18, эзетимиб, метформин.
Annotation: Kidneys play an important role in the human body. Prevention and effective treatment of kidney damage are one of the current challenges. The following article demonstrates the importance of using the biomarker interleukin-18 in early diagnosis of kidney damage. Interleukin-18 is an important biomarker of kidney damage in metabolic syndrome.
Keywords: metabolic syndrome, kidney damage, interleukin-18, ezetimibe, metformin.
Izoh.Inson organizmida buyraklar muhim ahamiyat kasb etadi. Buyraklar shikastlanishini oldini olish va ularni samarali davolash hozirgi kundagi dolzarb muammolardan biridir. Quyidagi maqolada interleykin-18 biomarkeridan foydalanib buyraklar shikastlanishini erta tashxislashda ahamiyati ko’rsatilgan. Interleykin-18 metabolik sindromda buyrak shikastlanishining muhim biomarkeri hisoblanadi.
Kalit so’zlar: metabolik sindrom, buyrak shikastlanishi, interleykin-18, ezetimib, metformin.
References
- 1. Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. JAMA. 2019 Dec 24;322(13):1294–1304;
- 2. Hall JE, Guyton AC. Guyton and Hall Textbook of Medical Physiology. 14th ed. Elsevier. 2021. Chapter: Renal Regulation of Body Fluids and Homeostasis. PMID: 33931265;
- 3. Kawanami D, Matoba K, Takeda Y, Nagai Y, Akamine T, Yokota T, Utsunomiya K. SGLT2 inhibitors as a therapeutic option for diabetic nephropathy. Int J Mol Sci. 2020 Sep 10;21(18):E6825;
- 4. Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A. Acute kidney injury. Nat Rev Dis Primers. 2021 Feb 25;7(1):52. doi: 10.1038/s41572-021-00284-z;
- 5. Kellum JA, Sileanu FE, Murugan R, Lucko N, Shaw AD, Clermont G. Classifying AKI by urine output versus serum creatinine level. J Am Soc Nephrol. 2021 Mar;32(3):742–751;
- 6. Liu Y, Chen X, Huang S, et al. Inflammation and fibrosis in diabetic kidney disease: new insights and therapeutic perspectives. Front Endocrinol (Lausanne). 2022 Aug 18;13:960212;
- 7. McCullough PA, Shaw AD, Haase M, Bouchard J, Waikar SS, Siew ED, Murray PT, Mehta RL. Diagnosis of acute kidney injury using functional and injury biomarkers: workgroup statements from the Acute Disease Quality Initiative Consensus Conference. Kidney Int. 2021 Apr;99(4):817–835;
- 8. Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, García-Pérez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2021 Jun;17(6):327–340;
- 9. Ostermann M, Bellomo R, Burdmann EA, et al. Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney Int. 2020 Jul;98(2):294–309;
- 10. Ostermann M, Zarbock A, Goldstein S, Kashani K, Macedo E, Murugan R, Bell M, Forni L. Recommendations on acute kidney injury biomarkers from the Acute Disease Quality Initiative Consensus Conference. Nat Rev Nephrol. 2022 Jun;18(6):351–369;
- 11. Pavkov ME, Nelson RG, Knowler WC, Cheng YJ, Krolewski AS, Niewczas MA. Elevation of urinary IL-18 precedes the development of diabetic kidney disease and predicts progression. Kidney Int. 2021 Oct;100(4):880–889
- 12. Paoli A, Rubini A, Volek JS, Grimaldi KA. Beyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets. Eur J Clin Nutr. 2020 Jul;74(7):1075–1093.
- 13. White C.A. Akbari A., Allen C., et al. Simultaneous glomerular filtration rate determination using inulin, iohexol, and 99mTc-DTPA demonstrates the need for customized measurement protocols. Kidney Int. 2021; 99 (4): 957-66.
- 14. Zarbock A, Kellum JA, Schmidt C, Van Aken H, Wempe C, Pavenstädt H, Meersch M. Effect of early versus delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury. Nat Rev Nephrol. 2022 Jan;18(1):7–20;
- 15. Zhang Z, Lu B, Sheng X, Jin N. Cystatin C in prediction of acute kidney injury: a systemic review and meta-analysis. Crit Care. 2021 Mar 8;25(1):111;